Zymeworks completes Theravance Biopharma buyout, adds new assets and revenue streams
Zymeworks has wrapped up its takeover of Theravance Biopharma, adding new drugs and royalties to its portfolio and pushing for steadier revenue.
Theravance Biopharma 1 article
Theravance Biopharma occupies a defined biopharma niche through ampreloxetine norepinephrine reuptake inhibition and neurogenic orthostatic hypotension therapeutics, consistent with its role as a biopharmaceutical company. A mechanistic view of Theravance Biopharma includes peripheral sympathetic norepinephrine modulation, nebulized COPD maintenance therapy and autonomic nervous system therapeutics, rather than treating the company as a generic therapeutic developer. This framing preserves Theravance Biopharma as the company entity, with organ-selective medicines contributing context without collapsing products, targets and modalities together.